SABCS Abstract Excerpt : Background C-C Chemoki
Post# of 148190
(Total Views: 479)
Posted On: 12/07/2021 3:15:04 PM
SABCS Abstract Excerpt :
Background C-C Chemokine Ligand type-5 (CCR5) is overexpressed in >95% of TNBC and has been
correlated with disease progression. Moreover, enhancement of DNA repair signaling by CCR5 activation
may contribute to chemotherapy resistance. Therefore, blocking CCR5 may result in increased immune
response against tumor cells and synergize with chemotherapy.
Read More: https://investorshangout.com/post/view?id=629...z7EOU0EMnB
Is there any other Mab or any other medical treatment that has a more profound effect on CCR 5 and the CCR ligand? I cannot reasonably fathom how LL will not prove beneficial to TNBC patients. The overexpression is so telling it is almost predictive.
Background C-C Chemokine Ligand type-5 (CCR5) is overexpressed in >95% of TNBC and has been
correlated with disease progression. Moreover, enhancement of DNA repair signaling by CCR5 activation
may contribute to chemotherapy resistance. Therefore, blocking CCR5 may result in increased immune
response against tumor cells and synergize with chemotherapy.
Read More: https://investorshangout.com/post/view?id=629...z7EOU0EMnB
Is there any other Mab or any other medical treatment that has a more profound effect on CCR 5 and the CCR ligand? I cannot reasonably fathom how LL will not prove beneficial to TNBC patients. The overexpression is so telling it is almost predictive.
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼